SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC] - N0000193948

Pharmacologic Class Information

Pharmacologic Code N0000193948
Pharmacologic Name SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor
Pharmacologic Uses
  • SARS-CoV-2 nucleotide analog RNA polymerase inhibitor
Pharmacologic Concept Established Pharmacologic Classes - [EPC]
Pharmacologic Concept Description An established pharmacologic class is a term or phrase that is scientifically valid and clinically meaningful according to the following definitions:
  • A scientifically valid pharmacologic class is supported by documented and submitted empiric evidence showing that the drug's pharmacologic class is known, not theoretical, and relevant and specific to the indication.
  • A clinically meaningful pharmacologic class term or phrase enhances the ability of professionals to understand physiologic effects related to the indication or to anticipate undesirable effects that may be associated with the drug or pharmacologic class.

NDC Products with SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor

The following table contains 3 products whose active ingredient are classified under the same pharmacologic class SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor [EPC].

NDC Proprietary Name Non-Proprietary Name Dosage Form Route Name Company Name Status
61958-2901Veklury Non-Proprietary Name: RemdesivirInjection, Powder, Lyophilized, For SolutionIntravenousGilead Sciences, Inc.ACTIVE
61958-2902Veklury Non-Proprietary Name: RemdesivirInjectionIntravenousGilead Sciences, Inc.ACTIVE